Ovarian carcinoma: Clinical validity by simultaneous determination of fibrin degradation products with the DR-70™ immunoassay and CA-125

Geburtshilfe und Frauenheilkunde

Volumn 66, Issue 1, 2006, Pages 68-75

  Schaffrath, M ^a   Harter, P ^b   Wulgaris, S ^a   Seufert, R ^a   Du Bois, A ^b   Pollow, K ^a,c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b DR HORST SCHMIDT KLINIKEN   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

DR 70 ; Immunoassay; Ovarian carcinoma; Tumor marker

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CATHEPSIN; FIBRIN DEGRADATION PRODUCT; PACLITAXEL; PLASMINOGEN ACTIVATOR; PROTEINASE; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER CELL; COLON CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PREOPERATIVE EVALUATION; RECTUM CANCER; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; STOMACH CANCER; UTERUS CANCER; VALIDATION PROCESS;

EID: 33644600945     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-923771     Document Type: Article

References (32)

1. Hiramoto R, Berneck J, Jurandowski J et al. Fibrin in human tumors. Cancer Res 1960; 20: 592-593
2. Graeff H, Klaubert W, Klaubert E, Gollwitzer R, von Hugo R, Harter R. Markerfunktion von quervernetzten Fibrinderivaten im Aszites beim Ovarialkarzinom: Ein Vergleich zu Aszites bei Leberzirrhose. Geburtsh Frauenheilk 1983; 43: 42-46
3. Franke M, Hafter R, von Hugo R, Röbl M, Graeff H. Ein Test zum Nachweis von Fibrin im Plasma. Geburtsh u Fauenheilk 1986; 46: 105-109
4. Schröck R, Hafter R, Schmid L, Babic R, Ulm K, Gössner W, Graeff H. Tumorassoziierte Antigene und Fibrinderivate als Reaktionsprodukte des Ovarialkarzinoms. Geburtsh Frauenheilk 1986; 46: 1-10
5. Wilhelm O, Hafter R, Coppenrath E, Pflanz MA, Schmitt M, Babic R, Linke R, Gössner W, Graeff H. Fibrin-fibrinectin compounds in human ovarian tumor ascites and their possible relation to the tumor stroma. Cancer Research 1988; 48: 3507-3514
6. Wilhelm O, Hafter R, Hernschen A, Schmitt M, Graeff H. Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma. Blood 1990; 75: 1673-1678
7. Graeff H, Jänicke F, Schmitt M. Klinische und prognostische Bedeutung tumorassoziierter Proteasen in der gynäkologischen Onkologie. Geburtsh Frauenheilk; 1991; 51: 90-99
8. Ossowski L, Quigley JP, Kellermann GM et al. Fibrinolysis associated with oncogenic transformation. J Exp Med 1973; 138: 1056-1064
9. Sylven B. Lysosomal enzyme activity in the interstitial fluid of solid mouse tumour transplants. Eur J Cancer 1968; 4: 463-474
10. Sylven B. Cellular detachment by purified lysosomal Cathepsin B. Eur J Cancer 1968; 4: 559-562
11. Poole AR, Tiltman KJ, Recklies AD et al. Differences in secretion of the proteinase Cathepsin B at the edges of human breast carcinomas and fibroadenomas. Nature 1978; 273: 545-547
12. Keppler D, Abrahamson M, Sordot B. Secretion of Cathepsin B and tumor invasion. Biochem Sac Trans 1994; 22: 43-49
13. Pietras RJ, Szego CM, Roberts JA et al. Lysosomal Cathepsin B-like activity: mobilization in prereplicative and neoplastic epithelial cells. J Histochem Cytochem 1981; 29: 440-450
14. Dickson RB, Shi YE, Johnson MD. A novel matrix-degrading protease in hormon-dependent breast cancer. Biochem Sac Trans 1994; 22: 49-52
15. Goldberg GI, Eisen AZ. Extracellular matrix metalloproteinases in tumor invasion and metastasis. In: Lippman ME, Dickson RB (eds). Regulatory Mechanisms in Breast Cancer. Boston: Kluwer Academic Publishers, 1990: 421-440
16. Wu D, Zhou X, Yang G, Xie Y, Hu M, Wu Z, Yang G, Lu M. Clinical performance of the AMDL DR-70™ Immunoassay kit for cancer detection. J Immunoassay 1998; 19: 63-72
17. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with ovarian carcinoma. J Clin Invest 1981; 68: 1331-1337
18. Bast RC, Klug TL, St John E, Jenison E, Nieloff JM. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883-887
19. Bast RC, Klug TL, Schaetzl E et al. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19.9 and carcinomaembryonic antigen. Am J Obstet Gynecol 1984; 149: 553-559
20. Bast RC Siegal FP, Runowicz C et al. Elevation of serum CA 125 prior to diagnosis of an epthelial ovarian carcinoma. Gynecol Oncol 1985; 22: 115-120
21. Brioschi PA, Irion O, Bischof P, Bader M, Forni M, Krauer F. Serum CA 125 in epithelial ovarian cancer. A longitudinal study. British J Obstet Gynaecol 1987; 94: 196-201
22. Brioschi PA, Bischof P, Rapin C, De Roten M, Irion O, Krauer F. Longitudinal study of CEA and CA 125 in ovarian cancer. Gynecol Oncol 1985; 21: 1-6
23. Chatal JF, Ricolleau G, Fumoleau P, Kremer M, Curtet C, Douillard JY. Radioimmunoassay of the CA 125 antigen in epithelial ovarian carcinomas. Cancer Detect Prevent 1983; 6: 624-629
24. Crombach G, Zippel HH, Würz H. Erfahrungen mit CA 125, einem Tumormarker für maligne epitheliale Ovarialtumoren. Geburtsh Frauenheilk 1985; 45: 205
25. Kaesemann H, Caffier H. Aussagekraft der Tumormarker TPA und CA 125 in der Verlaufskontrolle des Ovarialkarzinoms. 1984; 120: 545
26. Kaesemann H, Caffier H, Paulick R. Aussagekraft des Tumormarkers CA 125 beim Ovarialkarzinom. In: Von Greten H, Klapdor R (eds). Neue tumorassoziierte Antigene. Stuttgart: Thieme, 1985: 136-148
27. Kreienberg R, Möbus V. Die Bedeutung von Ca 125 im Vergleich zu anderen Tumormarkern beim Ovarialkarzinom. In: Von Greten H, Klapdor R (eds). Neue tumorassoziierte Antigene. Stuttgart: Thieme, 1985: 197-211
28. Ricolleau G, Chatal JF, Fumoleau P, Kremer M, Douillard JY, Cortet C, Radioimmunoassay of the CA 125 antigen in ovarian carcinomas: advantages compared with CA 19-9 and CEA. Tumor Biology 1984; 5: 151-159
29. Malkasian GD, Knapp RC, Lavin PT, Zurawski VR, Podratz KC, Stanhope CR, Mortel R, Berek JS, Bast RC, Ritts RE. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988; 159: 341-346
30. Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA 125: a prospective clinical assessment of its role as a tumor marker. Br J Cancer 1984; 50: 765-769
31. Kaesemann H, Caffier H, Hoffmann FJ, Crombach G, Würz H, Kreienberg R, Möbus V, Schmidt-Rhode P, Sturm G. Monoklonale Antikörper in Diagnostik und Verlaufskontrolle des Ovarialkarzinoms: CA 125 als Tumormarker. Klin Wochenschr 1986; 64: 781-785
32. Oehr P, Derigs G, Altmann R. Evaluation and characterization of tumor-associated antigens by conversion of inverse distribution function values into specificity-sensitivity diagrams. Tumor Diagnostik 1981; 2: 283-290